The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study to test the safety and activity of pembrolizumab (anti-PD-1) and trebananib (angiopoietin-2 inhibitor [Ang-2]) in patients with advanced solid tumors: Updated analysis of the colorectal cancer (CRC) cohort.
 
Osama E. Rahma
Employment - Outcomes4me; Outcomes4me; Outcomes4me; Outcomes4me
Leadership - Outcomes4me; Outcomes4me; Outcomes4me; Outcomes4me
Honoraria - Alaunus Global; Alaunus Global; Alaunus Global; Alaunus Global; Clinical Care Options; Clinical Care Options; Clinical Care Options; Clinical Care Options; Leerink; Leerink; Leerink; Leerink; Merck; Merck; Merck; Merck; MI Bioresearch; MI Bioresearch; MI Bioresearch; MI Bioresearch; PRMA Consulting; PRMA Consulting; PRMA Consulting; PRMA Consulting
Consulting or Advisory Role - Alcimed; Alcimed; Alcimed; Alcimed; Celgene; Celgene; Celgene; Celgene; Defined Health; Defined Health; Defined Health; Defined Health; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Genentech; Genentech; Genentech; Genentech; Gfk; Gfk; Gfk; Gfk; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Imvax; Imvax; Imvax; Imvax; Leerink; Leerink; Leerink; Leerink; Leerink; Leerink; Leerink; Leerink; Maverick Therapeutics; Maverick Therapeutics; Maverick Therapeutics; Maverick Therapeutics; Merck; Merck; Merck; Merck; PureTech; PureTech; PureTech; PureTech; Putnam Associates; Putnam Associates; Putnam Associates; Putnam Associates
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Merck; Merck; Merck; Merck
Patents, Royalties, Other Intellectual Property - PD-1/PD-L1 (Inst); PD-1/PD-L1 (Inst); PD-1/PD-L1 (Inst); PD-1/PD-L1 (Inst); Pending patent (DFCI 2386.010) (Inst); Pending patent (DFCI 2386.010) (Inst); Pending patent (DFCI 2386.010) (Inst); Pending patent (DFCI 2386.010) (Inst)
Travel, Accommodations, Expenses - Clinical Care Options; Clinical Care Options; Clinical Care Options; Clinical Care Options; Genentech; Genentech; Genentech; Genentech; Merck; Merck; Merck; Merck; PRMA Consulting; PRMA Consulting; PRMA Consulting; PRMA Consulting; PureTech; PureTech; PureTech; PureTech
 
James M. Cleary
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Research Funding - Merck; Merck; Merck; Merck; Tesaro; Tesaro; Tesaro; Tesaro
Travel, Accommodations, Expenses - Agios; Agios; Agios; Agios; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Roche; Roche; Roche; Roche
 
Kimmie Ng
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Lilly; Lilly; Lilly; Lilly; Seagen; Seagen; Seagen; Seagen; Tarrex Biopharma; Tarrex Biopharma; Tarrex Biopharma; Tarrex Biopharma
Research Funding - Celgene; Celgene; Celgene; Celgene; Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Pharmavite (Inst); Pharmavite (Inst); Pharmavite (Inst); Pharmavite (Inst); Trovagene; Trovagene; Trovagene; Trovagene
 
Benjamin L. Schlechter
No Relationships to Disclose
 
Jessica Eno
No Relationships to Disclose
 
Anna Maloney
No Relationships to Disclose
 
Anita Giobbie-Hurder
No Relationships to Disclose
 
David F. McDermott
Consulting or Advisory Role - alkermes; alkermes; alkermes; alkermes; Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; EMD Serono; EMD Serono; EMD Serono; exelixis; exelixis; exelixis; exelixis; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Peloton Therapeutics; Peloton Therapeutics; Peloton Therapeutics; Peloton Therapeutics; Pfizer; Pfizer; Pfizer; Pfizer
Research Funding - alkermes (Inst); alkermes (Inst); alkermes (Inst); alkermes (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Peloton Therapeutics (Inst); Peloton Therapeutics (Inst); Peloton Therapeutics (Inst); Prometheus (Inst); Prometheus (Inst); Prometheus (Inst); Prometheus (Inst)
Other Relationship - Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health; Apricity Health; Apricity Health; Apricity Health; Torque; Torque; Torque; Torque
Consulting or Advisory Role - 7 Hills Pharma; 7 Hills Pharma; 7 Hills Pharma; 7 Hills Pharma; Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Compass Therapeutics; Compass Therapeutics; Compass Therapeutics; Compass Therapeutics; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Partners Therapeutics; Partners Therapeutics; Partners Therapeutics; Partners Therapeutics; Partners Therapeutics; Partners Therapeutics; Partners Therapeutics; Partners Therapeutics; Pfizer; Pfizer; Pfizer; Pfizer; Pionyr; Pionyr; Pionyr; Pionyr; Rheos Medicines; Rheos Medicines; Rheos Medicines; Rheos Medicines; Sanofi; Sanofi; Sanofi; Sanofi; Surface Oncology; Surface Oncology; Surface Oncology; Surface Oncology; Takeda; Takeda; Takeda; Takeda; Torque; Torque; Torque; Torque; Verastem; Verastem; Verastem; Verastem
Research Funding - bristol-myers squibb (Inst); bristol-myers squibb (Inst); bristol-myers squibb (Inst); bristol-myers squibb (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); novartis (Inst); novartis (Inst); novartis (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); Methods of Using Pembrolizumab and Trebananib (Inst); Methods of Using Pembrolizumab and Trebananib (Inst); Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending as per institutional policy; patent pending as per institutional policy; patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Novartis; Novartis; Novartis; Novartis
Other Relationship - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche